A randomized, double-blind, three-arm, parallel group, single-dose phase I study to evaluate the pharmacokinetic similarity between SB12 (a proposed eculizumab biosimilar) and eculizumab (Soliris) in healthy subjects. | Int J Clin Pharmacol Ther;60(6): 269-279, 2022 Jun. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

A randomized, double-blind, three-arm, parallel group, single-dose phase I study to evaluate the pharmacokinetic similarity between SB12 (a proposed eculizumab biosimilar) and eculizumab (Soliris) in healthy subjects.

Lee, Hyun A; Jang, Hyerin; Jeong, Deokyoon; Kim, Younsoo; Fuhr, Rainard.

Int J Clin Pharmacol Ther ; 60(6): 269-279, 2022 Jun.

Article in En | MEDLINE | ID: mdl-35348111

Subject(s)

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biosimilar Pharmaceuticals Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Humans Language: En Journal: Int J Clin Pharmacol Ther Journal subject: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2022 Document type: Article Country of publication:

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biosimilar Pharmaceuticals Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Humans Language: En Journal: Int J Clin Pharmacol Ther Journal subject: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2022 Document type: Article Country of publication: